These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 35439284)

  • 21. Implementation Strategies Addressing Stakeholder-Perceived Barriers and Enablers to the Establishment of a Beta-Lactam Antibiotic Therapeutic Drug Monitoring Program: A Qualitative Analysis.
    Pai Mangalore R; Udy AA; Peel TN; Peleg AY; Ayton D
    Ther Drug Monit; 2024 Jun; 46(3):351-362. PubMed ID: 38018820
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The clinical application of beta-lactam antibiotic therapeutic drug monitoring in the critical care setting.
    Pai Mangalore R; Peel TN; Udy AA; Peleg AY
    J Antimicrob Chemother; 2023 Oct; 78(10):2395-2405. PubMed ID: 37466209
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapeutic drug monitoring of β-lactam antibiotics in the ICU.
    Dhaese S; Van Vooren S; Boelens J; De Waele J
    Expert Rev Anti Infect Ther; 2020 Nov; 18(11):1155-1164. PubMed ID: 32597263
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Compete or commit: Preferences for early commitment process or ASHP Match among pharmacy residency program directors and residents.
    Cleverdon K; Fisher AK; Mason B; Nguyen E
    Am J Health Syst Pharm; 2020 Sep; 77(19):1612-1618. PubMed ID: 34279585
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Geriatric pharmacy training requirements: A survey of residency programs.
    Niehoff KM; Jeffery SM
    Am J Health Syst Pharm; 2016 Feb; 73(4):229-34. PubMed ID: 26843500
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of therapeutic drug monitoring of beta-lactam and fluoroquinolones on clinical outcome in critically ill patients: the DOLPHIN trial protocol of a multi-centre randomised controlled trial.
    Abdulla A; Ewoldt TMJ; Hunfeld NGM; Muller AE; Rietdijk WJR; Polinder S; van Gelder T; Endeman H; Koch BCP
    BMC Infect Dis; 2020 Jan; 20(1):57. PubMed ID: 31952493
    [TBL] [Abstract][Full Text] [Related]  

  • 27. International consensus recommendations for the use of prolonged-infusion beta-lactam antibiotics: Endorsed by the American College of Clinical Pharmacy, British Society for Antimicrobial Chemotherapy, Cystic Fibrosis Foundation, European Society of Clinical Microbiology and Infectious Diseases, Infectious Diseases Society of America, Society of Critical Care Medicine, and Society of Infectious Diseases Pharmacists: An executive summary.
    Hong LT; Downes KJ; FakhriRavari A; Abdul-Mutakabbir JC; Kuti JL; Jorgensen S; Young DC; Alshaer MH; Bassetti M; Bonomo RA; Gilchrist M; Jang SM; Lodise T; Roberts JA; Tängdén T; Zuppa A; Scheetz MH
    Pharmacotherapy; 2023 Aug; 43(8):736-739. PubMed ID: 37615244
    [TBL] [Abstract][Full Text] [Related]  

  • 28. International consensus recommendations for the use of prolonged-infusion beta-lactam antibiotics: Endorsed by the American College of Clinical Pharmacy, British Society for Antimicrobial Chemotherapy, Cystic Fibrosis Foundation, European Society of Clinical Microbiology and Infectious Diseases, Infectious Diseases Society of America, Society of Critical Care Medicine, and Society of Infectious Diseases Pharmacists.
    Hong LT; Downes KJ; FakhriRavari A; Abdul-Mutakabbir JC; Kuti JL; Jorgensen S; Young DC; Alshaer MH; Bassetti M; Bonomo RA; Gilchrist M; Jang SM; Lodise T; Roberts JA; Tängdén T; Zuppa A; Scheetz MH
    Pharmacotherapy; 2023 Aug; 43(8):740-777. PubMed ID: 37615245
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Experience with Implementing a Beta-lactam Therapeutic Drug Monitoring Service in a Burn Intensive Care Unit: A Retrospective Chart Review.
    Alshaer M; Mazirka P; Burch G; Peloquin C; Drabick Z; Carson J
    J Burn Care Res; 2023 Jan; 44(1):121-128. PubMed ID: 35896122
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 'How to' Guide for Pharmacist-led Implementation of Beta-Lactam Therapeutic Drug Monitoring in the Critically Ill.
    Ausman SE; Moreland-Head LN; Abu Saleh OM; Jannetto PJ; Rivera CG; Stevens RW; Wessel RJ; Wieruszewski PM; Barreto EF;
    J Am Coll Clin Pharm; 2023 Aug; 6(8):964-975. PubMed ID: 37731602
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Needs assessment for developing a program to help train advanced-practice pharmacists for research.
    Bulkley CF; Miller MJ; Bush CG; Nussbaum BB; Draugalis JR
    Am J Health Syst Pharm; 2017 Dec; 74(23):1986-1995. PubMed ID: 29167140
    [TBL] [Abstract][Full Text] [Related]  

  • 32. β-Lactam Therapeutic Drug Monitoring in Critically Ill Patients: Weighing the Challenges and Opportunities to Assess Clinical Value.
    Dilworth TJ; Schulz LT; Micek ST; Kollef MH; Rose WE
    Crit Care Explor; 2022 Jul; 4(7):e0726. PubMed ID: 35815181
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Emergency medicine pharmacist market perceptions: Emergency medicine residency program directors and directors of pharmacy.
    Hu D; Myres J
    J Am Pharm Assoc (2003); 2020; 60(4):541-547.e2. PubMed ID: 32115391
    [TBL] [Abstract][Full Text] [Related]  

  • 34. β-Lactam therapeutic drug monitoring in the critically ill: optimising drug exposure in patients with fluctuating renal function and hypoalbuminaemia.
    Hayashi Y; Lipman J; Udy AA; Ng M; McWhinney B; Ungerer J; Lust K; Roberts JA
    Int J Antimicrob Agents; 2013 Feb; 41(2):162-6. PubMed ID: 23153962
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assays for therapeutic drug monitoring of β-lactam antibiotics: A structured review.
    Carlier M; Stove V; Wallis SC; De Waele JJ; Verstraete AG; Lipman J; Roberts JA
    Int J Antimicrob Agents; 2015 Oct; 46(4):367-75. PubMed ID: 26271599
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper
    Abdul-Aziz MH; Alffenaar JC; Bassetti M; Bracht H; Dimopoulos G; Marriott D; Neely MN; Paiva JA; Pea F; Sjovall F; Timsit JF; Udy AA; Wicha SG; Zeitlinger M; De Waele JJ; Roberts JA; ; ; ;
    Intensive Care Med; 2020 Jun; 46(6):1127-1153. PubMed ID: 32383061
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Implementation of a pharmacy residency resiliency program for PGY1 and PGY2 residents: Program structure and resident perceptions.
    Kneuss TG; Wolff AS; Meadors PL; Reynolds DR; Hammer JM
    Am J Health Syst Pharm; 2022 Jul; 79(15):1290-1295. PubMed ID: 35439812
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Learning Experiences Within Infectious Diseases Pharmacy Residency Programs in the United States: A Cross-Sectional Survey.
    Cho JC; Crotty MP; Kufel WD; Chahine EB; Sofjan AK; Gallagher JC; Estrada SJ
    Open Forum Infect Dis; 2019 Oct; 6(10):ofz387. PubMed ID: 31660350
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Survey Study of Gastroenterologists' Attitudes and Barriers Toward Therapeutic Drug Monitoring of Anti-TNF Therapy in Inflammatory Bowel Disease.
    Grossberg LB; Papamichael K; Feuerstein JD; Siegel CA; Ullman TA; Cheifetz AS
    Inflamm Bowel Dis; 2017 Dec; 24(1):191-197. PubMed ID: 29272486
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association between postgraduate year 2 residency program characteristics and primary project publication.
    Swanson JM; Shafeeq H; Hammond DA; Li C; Devlin JW
    Am J Health Syst Pharm; 2018 Mar; 75(6):384-391. PubMed ID: 29523535
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.